These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30178242)

  • 1. Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma.
    Gleeson FC; Levy MJ
    Curr Treat Options Gastroenterol; 2018 Dec; 16(4):441-448. PubMed ID: 30178242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
    Singh RR; Goldberg J; Varghese AM; Yu KH; Park W; O'Reilly EM
    Cancer Treat Rev; 2019 May; 75():27-38. PubMed ID: 30927677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.
    Gao Y; Chen MK; Chu YY; Yang L; Yu D; Liu Y; Hung MC
    Am J Cancer Res; 2021; 11(1):236-250. PubMed ID: 33520371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy.
    Pihlak R; Weaver JMJ; Valle JW; McNamara MG
    Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29329208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic ductal adenocarcinoma in the era of precision medicine.
    Zheng-Lin B; O'Reilly EM
    Semin Oncol; 2021 Feb; 48(1):19-33. PubMed ID: 33637355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
    Peters ML; Tseng JF; Miksad RA
    Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in precision medicine for pancreatic ductal adenocarcinoma.
    Hayashi H; Higashi T; Miyata T; Yamashita YI; Baba H
    Ann Gastroenterol Surg; 2021 Jul; 5(4):457-466. PubMed ID: 34337294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation.
    Meng F; Lu L; Tan Y; Duan Q; Lu H
    Front Oncol; 2021; 11():757965. PubMed ID: 34671564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.
    Hu ZI; Shia J; Stadler ZK; Varghese AM; Capanu M; Salo-Mullen E; Lowery MA; Diaz LA; Mandelker D; Yu KH; Zervoudakis A; Kelsen DP; Iacobuzio-Donahue CA; Klimstra DS; Saltz LB; Sahin IH; O'Reilly EM
    Clin Cancer Res; 2018 Mar; 24(6):1326-1336. PubMed ID: 29367431
    [No Abstract]   [Full Text] [Related]  

  • 12. Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care.
    Casolino R; Corbo V; Beer P; Hwang CI; Paiella S; Silvestri V; Ottini L; Biankin AV
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35805011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects.
    Wong W; Raufi AG; Safyan RA; Bates SE; Manji GA
    Cancer Manag Res; 2020; 12():2731-2742. PubMed ID: 32368150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging strategies in BRCA-positive pancreatic cancer.
    Kowalewski A; Szylberg Ł; Saganek M; Napiontek W; Antosik P; Grzanka D
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1503-1507. PubMed ID: 29777302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways.
    Yin C; Alqahtani A; Noel MS
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.
    Zhang J; Wolfgang CL; Zheng L
    Cancers (Basel); 2018 Jan; 10(2):. PubMed ID: 29385739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.
    Golan T; Javle M
    J Natl Compr Canc Netw; 2017 Aug; 15(8):1063-1069. PubMed ID: 28784866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma.
    Huffman BM; Ellis H; Jordan AC; Freed-Pastor WA; Perez K; Rubinson DA; Sethi N; Singh H; Surana R; Wolpin BM; Aguirre AJ; Cleary JM
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.